Do morphokinetic parameters vary between male and female preimplantation embryos?
Retrospective cohort study of 175 cycles between March 2018 to June 2021 from two reproductive centers. It included time-lapse data from 92 female and 83 male preimplantation embryos exclusively issued from fresh oocyte donation. Only fresh elective single-embryo transfers on day 5 were assessed and sex of the embryo was confirmed at birth. The morphokinetic parameters analyzed were measured in hours post insemination. A two-tailed Student's t-test was used to compare morphokinetics between embryo sexes and a p<0.05 was considered statistically significant.
Following strict inclusion criteria to avoid poor quality preimplantation embryos, no significant differences were found in morphokinetic parameters when comparing cycles that resulted in female vs. male live births: time to pronuclear fading (21.8±3.3 vs. 22.3±3.4 hpi; p>0.39); time to 2-cell stage (24.6±2.5 vs. 25.0±2.5 hpi; p>0.34); time to 3-cell stage (35.3±3.3 vs. 35.8±3.1 hpi; p>0.28); time to 4-cell stage (36.3±3.4 vs. 36.9±3.7 hpi; p>0.20); time to 5-cell stage (47.9±4.7 vs. 48.0±4.8 hpi; p>0.88); time to 8-cell stage (54.0±6.5 vs. 54.1±6.5 hpi; p>0.91); time to start of blastulation (86.3±14.6 vs 85.7±15.5 hpi; p>0.78) and time to full blastocyst stage (93.0±16.9 vs. 93.2±17.2 hpi; p>0.94).
There are no significant differences in morphokinetics between male and female preimplantation embryos
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Reproductive BioMedicine Online
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Juanjo Fraire-Zamora received a Biology degree from UNAM (Mexico), a PhD from University of California (USA) and a Master's degree in Human Assisted Reproductive Technologies from UPF (Spain). He is part of the data team at the EUGIN group and an active member of ESHRE.
Accepted: March 2, 2023
Received in revised form: February 10, 2023
Received: November 29, 2022
Publication stageIn Press Journal Pre-Proof
© 2023 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.